32results about How to "Suitable for injection" patented technology

The invention provides a crosslinking hyaluronic acid gel and its preparation method. The method is characterized in that divinylsulfone is combined with polyethylene glycol for generating a novel cross-linking agent at first, the novel cross-linking agent is reacted with a hyaluronic acid molecule for producing a crosslinking hyaluronic acid gel. The crosslinking sodium hyaluronate gel obtained in the invention has good biological compatibility and longer half life period, and the particle is small and uniform, and is suitable for beautifying shaping, tissue filling, bone articular lubrication or medicine sustained-release preparation and the like.

The invention discloses a cathode injection material, and a manufacturing method and an application thereof. The cathode injection material comprises nano-titanium dioxide and a cesium salt doped mutually. The manufacturing method comprises the following steps of: preparing a nano-titanium dioxide solution and a cesium salt solution respectively; mixing a nano-titanium dioxide solution dispersion system with the cesium salt solution to obtain a mixed solution; and coating the mixed solution onto a conductive substrate in a spinning way, and heating and drying to obtain the cathode injection material. The cathode injection material disclosed by the invention has the advantages of low cost, capability of effectively enhancing the input and the transmission of charges, increase in the LUMO energy level of a cathode when applied to an organic electroluminescent device, matching with the energy level of an organic electroluminescent structure, reduction in a potential barrier between the cathode injection material and the organic electroluminescent structure, more suitability for electron injection, increase in the electron injection efficiency, preferable increase in the light extraction capability of the organic electroluminescent device, high luminance and long service life. The manufacturing method of the cathode injection material has a simple procedure and high production efficiency.

The invention relates to glycyrrhetinic acid solid lipid nanoparticles and a preparation method for the same, belonging to the field of medicinal preparation. The main ingredients of the glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention comprise active raw material glycyrrhetinic acid, medicinal phospholipid, a lipid material and a surfactant. The glycyrrhetinic acid solid lipid nanoparticle solution and the freeze-dried powder injection thereof prepared by the preparation method disclosed by the invention are small in particle diameter, high in entrapment efficiency, good in stability and capable of being used for a plurality of administration routes such as oral administration and injection administration. The glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention can reduce dosage, enhance curative effect and reduce the toxic and side effects of medicine, as well as are suitable for treating a plurality of diseases such as hepatitis, liver cancer, lung cancer, ovarian cancer, gastritis, gastric cancer, leukaemia and aids.

The invention belongs to the field of pharmaceutical preparations and discloses a finasteride lyotropic liquid crystal gel preparation precursor. The finasteride lyotropic liquid crystal gel preparation precursor comprises the following raw materials in percentage by mass: 45-80% of phospholipid, 10-50% of glyceride, 5-9% of a cosolvent and 0.1-6% of finasteride. The finasteride in the finasteridelyotropic liquid crystal gel preparation precursor disclosed by the invention is uniformly dispersed; the precursor is low in viscosity and can be used for injection; after entering a human body, theprecursor can act with water to form the lyotropic liquid crystal with an excellent drug sustained release effect; the biocompatibility is excellent, no systemic inflammatory response is caused, andtoxic and side effects of the medicine are avoided; the drug administration frequency can be decreased; the precursor is low in cost, simple in preparation method and capable of easily realizing industrialization; the precursor can be used for treating male hair loss and benign prostatic hyperplasia, so that an enlarged prostate is shrunk, and symptoms brought by urine flow and benign prostatic hyperplasia are improved.

The invention relates to a drug rehabilitation and analgetic medicine and method for making the same, which comprises spheroidine, citric acid and distilled water. The medicine is highly effective, no drug dependency will be produced, no repetition will occur after ceasing application, so its adaptation human populations are wide.

The invention discloses rifaximin-containing in-situ gel for breast injection. The rifaximin-containing in-situ gel comprises the following components in percentage by mass: 0.1-15% of an active drug component existing in a dispersed way, 0.25-20% of an active drug component existing in an inclusion compound form, 12-30% of poloxamer 407, 0.01-11% of poloxamer 188, 0.01-10% of a polymer drag reduction agent, 0.001-3% of a bacterial inhibitor, a pH regulator for regulating the pH value to 5.5-7.5 and the balance of injection water. The invention also discloses a preparation method of the rifaximin-containing in-situ gel for breast injection. Water is used as a solvent, so that the rifaximin-containing in-situ gel is good in biocompatibility, little in irritation and high in safety, exists in a liquid state under a storage condition, is completely formed within 4-15 seconds after being injected to the breast because of thermal stimulation inside the breast and can be used for effectively treating, preventing and controlling mastitis of milk cows within the whole dry cow period; and in addition, the sustained-release effect is remarkable, and the in-vitro drug release time is long and reaches up to 48 days.

The invention provides a preparation of aseptic vitamin C composition, which comprises the steps of: preparing aseptic vitamin C sodium, preparing aseptic vitamin C and mixing the preparing aseptic vitamin C sodium and the aseptic vitamin C for preparing the composition, wherein in the preparation process of the aseptic vitamin C sodium comprises the steps of: adding antioxidant, complexing agent and activated carbon into the aqueous solution of the vitamin C sodium, and the like. The invention provides the aseptic vitamin C composition, and the application of the aseptic vitamin C composition in preparation of vitamin C powder injection.

The invention discloses a lansoprazole lipidosome injection which comprises 3 parts of lansoprazole, 3 to 6 parts of cholesterol, 6 to 9 parts of phospholipid, 0.1 to 0.5 part of an antioxygen and 3 to 6 parts of an excipient. The phospholipid is composed of HEPC (hydrogenated egg phosphatidylcholine), soya bean lecithin and stearic acid lecithin of which the weight ratio is 3-2 to 3-2 to 1. The lipidosome injection has the advantages of high encapsulation efficiency, low leakage rate, stability and the like, and has a relatively high clinic applicable value.

The invention discloses a nipple sealing agent for non-human animals. The nipple sealing agent is prepared from the following components in percentage by mass: 11 to 40 percent of temperature-sensitive in-situ gel matrix, 0.001 to 2 percent of ion-sensitive in-situ gel matrix, 5 to 20 percent of carbomer gel, 0.02 to 8 percent of chitosan, 0.01 to 5 percent of polymer retardant, 0.001 to 2 percentof bacteriostatic agent and the balance of water for injection, wherein the temperature-sensitive in-situ gel matrix is poloxamer, and the ion-sensitive in-situ gel matrix is gellan gum. The nipple sealing agent is mainly based on an in-situ gel system, the sensitivity to the environment in the nipple is greatly improved, the environment in the nipple can be perceived in time, and gelling is rapidly generated; the chitosan is added so that the gel strength can be effectively improved, a compact barrier can be formed, and invasion of pathogenic bacteria is hindered. The gel matrix is good in biocompatibility, can be adhered to the inner wall of a nipple hole, and can be remained in the nipple hole for a long time to cover the whole dry period.

The invention discloses an insulin injection site reminding machine. The insulin injection site reminding machine comprises an analog machine body. The analog machine body at least comprises a simulated trunk, simulated upper limbs and simulated lower limbs, and button switches corresponding to insulin injection sites are arranged on the simulated trunk, the simulated upper limbs and the simulated lower limbs respectively. Every time injection is conducted, a button switch, corresponding to a certain injection site, on the analog machine body is pressed down; after injection of all sites, a new round of site selection is conducted, so as to help people choose injection sites more conveniently. For injections with a long time interval, injection positions can be recorded conveniently by means of the insulin injection site reminding machine, and confusion can be avoided. The insulin injection site reminding machine can be carried by a patient conveniently, and is suitable for self-injection of the patient.

The invention discloses an artesunate preparation for injection. The artesunate preparation for injection includes sterile artesunate powder and an auxiliary material pH regulator powder for injection. The pH regulator for injection is one of disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium hydroxide and potassium hydroxide, or a mixture containing more of above substances according to an arbitrary ratio, and preferably one of the disodium hydrogen phosphate and dipotassium hydrogen phosphate or a mixture containing the disodium hydrogen phosphate and dipotassium hydrogen phosphate according to an arbitrary ratio. A molar ratio of the sterile artesunate to the pH regulator is 1:1 to 1:6, and preferably 1:1.0 to1:4.0. The above composition has obviously better solubility, solution stability and solid preparation stability than commercially available artesunate for injection, and is suitable for being clinically used.